Month: July 2022

Clutch Platform Powers Wizard World's First Loyalty Program for the Comic Con Crowd

Posted on by admin_EIS_

clutch

The producer of the iconic pop culture conventions enlists a marketing technology innovator to deliver personalized, more memorable experiences for fans.

When it comes to fan loyalty, there’s arguably no more devout group than the multitudes of decked-out fans attending Wizard World Comic Con events each year. Now the iconic tour’s producer, Wizard World, Inc. has teamed with Clutch, a consumer management platform pioneer, to further kindle fan devotion through enhanced, personalized experiences at its comic, sci-fi, and related events.

With its new fan loyalty program, Wizard World will offer exclusive incentives for advanced admission purchases along with options to pre-order photo op and autograph sessions at its pop culture events. The program will also help Wizard World use data insights provided by the Clutch platform to identify a fan’s favorite movies, TV shows, comics, and characters, and deliver customized experiences.

“With a fast-growing list of characters, brands, and celebrities participating in our comic con events, it is crucial to Wizard World and our partners that our offerings match specific fan preferences and deliver exactly what they are most passionate about,” explained John Macaluso, Wizard World CEO. “Clutch’s advanced customer marketing technology gives us keen insight into our fans’ behavior and interests, which allows us to cater to their individual preferences and maximize their experiences at all of our shows across the country.”

“Today’s consumers demand that brands deliver customized, even ‘special’ experiences, regardless of location, product, or scale,” said Chris Jones, Senior Vice President of Business Development for Clutch. “Personalization is critical to every customer-centric business, and it will come naturally for a brand like Wizard World that’s already had tremendous success with experiential marketing. The Clutch-Wizard World team is going to explore fan loyalty, events marketing, and data collection in a way that hasn’t been done before, creating untold growth opportunity for both organizations.”

The loyalty program is planned for full-scale deployment in the first quarter of 2016. In the meantime, you can see the conflux of devotees for yourself at the next Wizard World Comic Con, happening November 20-22 in Reno, Nevada.

About Clutch
Clutch’s advanced Consumer Management platform delivers customer intelligence and personalized engagements empowering consumer-focused brands to identify, understand and motivate their Most Valuable Customers (MVCs). Its advanced marketing platform integrates customer data across point-of-sale, ecommerce, mobile and social channels delivering personalized experiences, intelligent engagements and loyal customers.Headquartered outside of Philadelphia, Clutch’s solutions impact over 55 million consumers of over 750 brands. Clutch is a proud partner of Safeguard Scientifics SFE, +0.47% and Ben Franklin Technology Partners. For more information visit clutch.com, follow Clutch Holdings on LinkedIn or@ClutchSuccess on Twitter.

About Wizard World
Wizard World, Inc. (http://www.wizardworld.com) produces Comic Cons and pop culture conventions across North America that celebrate the best in pop-fi, pop culture, movies, television, cosplay, comics, graphic novels, toys, video gaming, sci-fi, gaming, original art, collectibles, contests and more. A first-class lineup of topical programming takes place at each event, with celebrity Q&A’s, comics-themed sessions, costume contests, movie screenings, evening parties and more. Wizard World has also launched CONtv, a digital media channel in partnership with leading independent content distributor Cinedigm™ (NASDAQ: CIDM), and ComicConBox™, a premium subscription-based monthly box service. Fans can interact with Wizard World on Facebook, Twitter, Pinterest, Instagram and other social media services.

The 2015-16 Wizard World Comic Con schedule is available at: www.wizardworld.com/wizcon.html.

Cagent Vascular Receives $9M Investment to Accelerate Marketing of its Lead Product

Posted on by admin_EIS_

A Wayne medical device company has raised $9 million to accelerate the commercialization of its peripheral artery disease device cleared by the Food and Drug Administration last year.

Cagent Vascular received the investment from Sectoral Asset Management. Marc-Andre Marcotte, a partner and COO at the Canadian investment firm, has joined Cagent’s board of directors.

Founded in 2014, Cagent specializes in developing next generation angioplasty balloons using its proprietary serration technology.

In April 2020, the FDA granted marketing clearance to the company’s Serranator PTA serration balloon catheter — an angioplasty device with serrated metal strips to aid in arterial expansion — for treating below-the-knee lesions.

Cagent intends to use part of the investment proceeds to accelerate the commercialization and scaling of manufacturing for the Serranator product.

Read the full article here.

Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

Posted on by admin_EIS_

WAYNE, Pa.–(BUSINESS WIRE)–

Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its Serranator® PTA Serration Balloon Catheter for treating below-the-knee (BTK) lesions.

The Serranator device is the first and only angioplasty balloon FDA Cleared and CE Marked that embeds serration technology into a semi-compliant balloon for treating Peripheral Artery Disease (PAD). It is designed to create multiple longitudinal lines of interrupted micro-serrations to aid arterial expansion.

The company also recently completed enrollment of its PRELUDE-BTK Study, a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of the device. A total of 49 patients were enrolled. The study is led by Principal Investigator, Dr. Andrew Holden (Auckland, New Zealand). Six centers from Europe and New Zealand are participating in the trial which will include 30-day and 6-month follow up.

“This trial enrolled quickly, which speaks to the enthusiasm for better technology like the Serranator. Treating BTK lesions is a challenge due to the unpredictability we often see with existing balloon therapy such as insufficient lumen gain, vessel dissection and recoil. These arteries are small in diameter, often calcified, with much of the disease located in the distal portion of the leg, making treatment a challenge,” stated Dr. Holden.

Read the full article here.

Biomeme & Predigen Merge to Enable Point-of-Care Delivery of Host Response Tests That Address Critical Unmet Needs in Healthcare

Posted on by admin_EIS_

Biomeme, the leading provider of portable PCR testing solutions, has signed a definitive agreement to acquire Predigen, a privately held diagnostic company and emerging leader in precision medicine focused on host response diagnostics.

Predigen’s acquisition will expand Biomeme’s capabilities across infectious disease and clinical microbiology, business management, and commercialization.

redigen’s portfolio includes flagship host gene expression biomarkers for the pre-symptomatic detection of viral infections as well as biomarkers that accurately discriminate viral from bacterial infections to enable appropriate patient management and antibiotic stewardship. Predigen also has signatures for sepsis diagnosis, sepsis risk stratification, and a pipeline of biomarkers for non-infectious diseases. With nine different patents at various stages of execution, this scientific team has received over $50 million in grant funding from the Department of Defense (DoD), National Institutes of Health (NIH), Department of Veterans Affairs (VA), and Department of Homeland Security (DHS).

According to Brian Best, Predigen’s CEO, “Prior to the pandemic, the over-utilization of antibiotics and increasing antimicrobial resistance were dominant concerns among the infectious disease community. That need still exists and it is a significant market opportunity that requires accurate, near-patient and rapid-result performance capabilities. This merger will enable an end-to-end solution to meet this challenge.”

Read the full article here.

Audigent Secures $19.1 Million Series B Financing Round Led by EPAM Systems/The Go Philly Fund

Posted on by admin_EIS_

Audigent, the “2.0” data management platform (DMP) and leading edge “data agency” that has pioneered data-driven private marketplace deals through its cookieless HALOM Identity product suite has announced that it has completed a $19.1 million Series B round of financing.

The funding will allow Audigent to continue its expansion as the premier first party data platform for the entertainment, sports, lifestyle and Direct-To-Consumer (DTC) eCommerce verticals as well as further its innovation as one of the leading next-gen data monetization platforms for major retail and CPG partners. The Go Philly Fund, a joint venture between Ben Franklin Technology Partners and EPAM Systems, Inc., has led the investment round with additional participation from both existing and new investors including: Broadscale Group, Raised in Space, MathCapital, Riverpark Ventures and others.

The investment brings Audigent’s total funding to $33.6 million since launch and will help the company broaden the reach of its cookieless PMP products and HALO IDTM while also aggressively expanding its sales and marketing efforts globally. Additionally, it will fuel the continued expansion of first-to-market data and inventory monetization tools for premium digital publishers. EPAM’s VP, Co-Head of North America, Regina Viadro will join the Board of Directors.

The Series B financing builds on an exciting year of growth for Audigent, highlighted by extraordinary demand for its SmartPMPTM and ContextualPMPTM products as well as growing adoption of its cookieless HALO IDTM by both content publishers and supply side platforms (SSP).

Read the full article here.

After a Pandemic Growth Spurt, COVID-19 Test Maker Biomeme is Moving its HQ to North Broad and Looking to the Future

Posted on by admin_EIS_

About this time last year, Biomeme — makers of a rapid COVID-19 test and other diagnostic hardware — had about 35 people in its 10th and Chestnut streets HQ.

Enter a global pandemic. The company, now about 280 employees across the U.S. and about 120 in the Philadelphia region, has outgrown its office. It will join esports company Nerd Street Gamers at a 44,000-square-foot office, lab, testing and manufacturing in a new corporate headquarters at 401 N. Broad St., owned by Netrality, operator of fiber-dense data centers that allow for super-fast internet.

Biomeme currently produces mobile, real time-PCR devices and other testing hardware. It’s currently manufacturing products including a FDA emergency use authorized COVID-19 test.

The move will help the expansion of the company’s manufacturing capacity, and is supported by a $3 million grant from Pennsylvania’s Redevelopment Assistance Capital Program. It will allow Biomeme to produce more than 10 million tests annually, the company said. Biomeme has been working with Strada Architecture LLC to build out the space to meet all of its office, manufacturing and lab needs.

Read the full article here.

×